Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;9(1):43-58.
doi: 10.21037/gs.2019.11.03.

Cardiovascular risk and mortality in patients with active and treated hypercortisolism

Dingfeng Li  1 , Omar M El Kawkgi  1 , Andres F Henriquez  1 , Irina Bancos  1
Affiliations
Review

Cardiovascular risk and mortality in patients with active and treated hypercortisolism

Dingfeng Li et al. Gland Surg. 2020 Feb.

Abstract

Patients with hypercortisolism demonstrate high cardiovascular morbidity and mortality, especially if diagnosis is delayed. Hypercortisolism-induced cardiovascular and metabolic comorbidities include hypertension, impaired glucose metabolism, dyslipidemia, and obesity. High prevalence of cardiovascular risk factors leads to increased rate of cardiovascular events and mortality. This risk is reduced, albeit not reversed even after successful treatment of hypercortisolism. In this review we will describe prevalence and mechanisms of cardiovascular comorbidities in patients with hypercortisolism. In addition, we will summarize the effect of therapy on cardiovascular risk factors, events, as well as mortality.

Keywords: Cushing syndrome (CS); cardiovascular events; dyslipidemia; glucose metabolism; hypertension; mild autonomous cortisol secretion (MACS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: IB served as consultant on advisory board of HRA Pharma. The other authors have no conflicts of interest to declare.

References

    1. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40. 10.1210/jc.2008-0125 - DOI - PMC - PubMed
    1. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf) 2011;75:436-42. 10.1111/j.1365-2265.2011.04124.x - DOI - PubMed
    1. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117-23. - PubMed
    1. Steffensen C, Bak AM, Rubeck KZ, et al. Epidemiology of Cushing's syndrome. Neuroendocrinology 2010;92 Suppl 1:1-5. 10.1159/000314297 - DOI - PubMed
    1. Valassi E, Santos A, Yaneva M, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011;165:383-92. 10.1530/EJE-11-0272 - DOI - PubMed